Concert Pharmaceuticals

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Concert Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#648 of 15,742 sponsors by registered trial count).

24 total trials none currently recruiting 24 completed early-phase tilt top decile by trial count

Concert Pharmaceuticals: 24 sponsored US clinical trials, none currently recruiting.

Concert Pharmaceuticals sponsors 24 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 24 completed. 2 of these trials are in Phase 3-4 (later-stage) and 22 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Health Volunteers, with 2 trials.

Top-decile sponsor footprint

Concert Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#648 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

A 90/100

24 of 24 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

24 total, page 1 of 1

COMPLETED Phase 1

Study to Evaluate Multiple Doses of Fluconazole, a CYP3A4 and CYP2C9 Inhibitor, on the Pharmacokinetics of CTP-543 in Healthy Subjects

NCT05478772

COMPLETED Phase 1

Study To Evaluate The Effect Of Multiple Doses of CTP-543 On The Pharmacokinetics Of Single Doses of Midazolam In Healthy Subjects

NCT05467709

COMPLETED Phase 1

Study of the Effect of Food on the Bioavailability of the To-Be-Marketed Formulation of CTP-543 in Healthy Volunteers

NCT05467696

COMPLETED Phase 1

Study to Assess the Effect of Renal Impairment on the Pharmacokinetics of CTP-543

NCT05468749

COMPLETED Phase 1

Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of CTP-543

NCT05467722

COMPLETED Phase 1

A Randomized Study to Evaluate the Effects of CTP-543 on the QT/QTc Intervals in Health Volunteers

NCT05192369

COMPLETED Phase 3

Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA2)

NCT04797650

COMPLETED Phase 1

Drug-drug Interaction Study of CTP-543 and Rifampin in Healthy Adult Subjects

NCT04843540

COMPLETED Phase 1

Drug-drug Interaction Study of CTP-543 and Itraconazole in Healthy Adult Subjects

NCT04743414

COMPLETED Phase 2

A Study to Evaluate the Durability of Response of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata

NCT04784533

COMPLETED Phase 3

Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA1)

NCT04518995

COMPLETED Phase 1

Drug-drug Interaction Study of CTP-543 and Oral Contraceptives in Healthy Female Subjects

NCT04309643

COMPLETED Phase 2

A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-692 as an Adjunctive Treatment in Adults With Schizophrenia

NCT04158687

COMPLETED Phase 1

Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers

NCT04092712

COMPLETED Phase 2

Efficacy and Tolerability Study of Two Dosing Regimens of CTP-543 in Adults With Alopecia Areata

NCT03941548

COMPLETED Phase 1

Multiple Ascending Dose Study of CTP-692 in Healthy Volunteers

NCT03880253

COMPLETED Phase 1

Food Effect Study of CTP-543 in Healthy Volunteers

NCT03880136

COMPLETED Phase 2

Efficacy and Tolerability Study of Two Dose Regimens of CTP-543 in Adults With Alopecia Areata

NCT03811912

COMPLETED Phase 1

Study to Assess the Safety and Pharmacokinetic (PK) of CTP-692 in Healthy Volunteers

NCT03830463

COMPLETED Phase 2

Study to Evaluate the Safety and Efficacy of CTP-543 in Adults With Moderate to Severe Alopecia Areata

NCT03137381

COMPLETED Phase 1

Open-Label Crossover Study Comparing CTP-543 to Jakafi®

NCT02960945

COMPLETED Phase 2

A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients

NCT01487109

COMPLETED Phase 1

Safety & Tolerability Study of CTP-499 in Patients With Moderate Chronic Kidney Disease

NCT01460199

COMPLETED Phase 1

Safety, Tolerability, and Pharmacokinetics (PK) of CTP-499

NCT01328821

Phase Distribution

PhaseTrial count
Phase 1 16
Phase 2 6
Phase 3 2

Therapeutic Areas

How the Concert Pharmaceuticals early-phase archive is shaped

24 indexed studies, none listed as recruiting (0% open); 24 completed (100%).

Phase mix: 2 late (III/IV) vs 22 early (I/II) (early-phase heavy).

Top condition: Health Volunteers (2 trials), 2 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Concert Pharmaceuticals: archived-pipeline peers nationwide

Peers matched on 24 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Concert Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015202530 0%10%20%30% Total trials Recruiting share Concert PharmaceuticalsAcrotech BiopharmaAgenusAkebia TherapeuticsBlueprint Medicines Corporation10xBio22nd Century Group23andMe3-C Institute for Social Development
Concert Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Concert Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 24 archived trials

Sponsors with similar archive density (± trial count)

What to do with this Concert Pharmaceuticals page

24 registered trials is a research-attention snapshot, not an endorsement of Concert Pharmaceuticals or any single study.

  • None of Concert Pharmaceuticals's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Health Volunteers is the condition Concert Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Health Volunteers trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Concert Pharmaceuticals pipeline card: 24 registered trials from official public datasets.Report a data error.